Method for inhibiting the expression of inflammation promoting factors
Inventors
Asahara, Hiroshi • Chiba, Tomoki • Abe, Kentaro
Assignees
Nippon Zoki Pharmaceutical Co Ltd • Tokyo Medical and Dental University NUC
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12066429-B2
Publication Date
2024-08-20
Expiration Date
Abstract
Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for the method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.
Core Innovation
RBMS2 is described as an mRNA post-transcriptional regulator of inflammation-promoting factors. RBMS2 regulates inflammation-promoting factor expression through AU-rich elements in 3′UTRs, including regulation of IL-6.
The patent describes RBMS2-based inhibitor and diagnostic frameworks centered on inhibiting RBMS2 expression and/or RBMS2 function. The disclosed inhibitor framework includes RBMS2-specific siRNA, RBMS2-specific antisense nucleic acid, and expression vectors thereof, and also references IL-10 as an inhibitor of RBMS2 expression.
For monitoring and clinical assessment, the disclosure describes screening indices and diagnosis/progression assessment based on RBMS2-related measurements. These include RBMS2 expression level, RBMS2-RNA binding to AU-rich element-containing RNA, and downstream AU-rich element-mRNA/protein levels, and RBMS2 expression-based assessment for immune, inflammatory, and painful diseases.
Claims Coverage
The document contains one independent claim, directed to inhibiting the expression of an inflammation promoting factor by administering RBMS2 expression and/or RBMS2 function inhibitors. The inventive features are limited to particular inflammation-promoting factors and particular RBMS2 inhibitors.
Inhibiting inflammation-promoting factor expression via RBMS2 inhibitors
Administering at least one RBMS2 expression inhibitor and/or at least one RBMS2 function inhibitor to a patient in need of inhibition of the expression of an inflammation promoting factor.
Target inflammation-promoting factors selected from IL-6, COX-2, IL-8, IL-1B, MMP1, and IL-24
Where the inflammation promoting factor is selected from the group consisting of IL-6, COX-2, IL-8, IL-1B, MMP1, and IL-24.
RBMS2 inhibitors limited to RBMS2-specific siRNA, RBMS2-specific antisense nucleic acid, and expression vectors thereof
Where the at least one RBMS2 expression inhibitor and/or the at least one RBMS2 function inhibitor is selected from the group consisting of a RBMS2-specific siRNA, a RBMS2-specific antisense nucleic acid, and expression vectors thereof.
Overall, the claim coverage is directed to patient treatment for inhibition of specific inflammation-promoting factors (IL-6, COX-2, IL-8, IL-1B, MMP1, and IL-24) by administering RBMS2-specific expression and/or function inhibitors limited to RBMS2-specific siRNA, RBMS2-specific antisense nucleic acids, and expression vectors thereof.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?